|Dr. Sean A. McCarthy||Chairman, CEO & Pres||957k||1.16M||1967|
|Mr. Frederick W. Gluck||Co-Founder & Independent Director||50.5k||N/A||1935|
|Mr. Carlos Campoy||Sr. VP & CFO||768.78k||N/A||1965|
|Mr. Lloyd A. Rowland Jr., J.D.||Sr. VP, Gen. Counsel, Chief Compliance Officer & Sec.||574.82k||N/A||1957|
|Dr. Amy C. Peterson M.D.||Exec. VP & Chief Devel. Officer||804.8k||N/A||1967|
|Dr. Alison L. Hannah||Sr. VP & Chief Medical Officer||654.56k||N/A||1961|
|Dr. Chau Cheng M.B.A., Ph.D.||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Ms. Danielle Olander||Sr. VP, Talent & Systems Devel.||N/A||N/A||N/A|
|Ms. Alison Joly||Sr. VP of Program & Alliance Management||N/A||N/A||N/A|
|Ms. Leslie Robbins||Sr. VP of Intellectual Property||N/A||N/A||N/A|
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
CytomX Therapeutics, Inc.’s ISS governance QualityScore as of 1 June 2021 is 7. The pillar scores are Audit: 5; Board: 7; Shareholder rights: 4; Compensation: 9.